Use of dupilumab to manage a grade 3 cutaneous adverse effect from enfortumab vedotin/pembrolizumab treatment in a patient with metastatic urothelial carcinoma

書目詳細資料
發表在:	JAAD Case Reports
Main Authors:	Maura C. Gillis, BA, Vanessa R. Weir, BA, Cecilia Lezcano, MD, Gopa Iyer, MD, Allison Gordon, MD
格式:	Article
語言:	英语
出版:	Elsevier 2025-02-01
主題:	bullous dupilumab enfortumab vedotin flexural oncodermatology pembrolizumab
在線閱讀:	http://www.sciencedirect.com/science/article/pii/S235251262400417X

因特網